SynthesisBMC gastroenterology2021
Alterations in short-chain fatty acids and serotonin in irritable bowel syndrome: a systematic review and meta-analysis.
Synthesis in BMC gastroenterology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 1 synthesis or guideline pooled it, 41 citations in OpenAlex.
- Changes in Fecal Short-Chain Fatty Acids in IBS Patients and Effects of Different Interventions: A Systematic Review and Meta-Analysis.Nutrients · 2024Pooled it
- The Impact of Irritable Bowel Syndrome on Spine Surgery Outcomes: A Comprehensive Narrative Review.Journal of clinical medicine · 2026Review
- Altered gut microbial functional pathways in people with irritable bowel syndrome enable precision health insights.BMC gastroenterology · 2025Article
- From gums to moods: Exploring the impact of the oral microbiota on depression.Brain, behavior, & immunity - health · 2025Review
- Advancements in the Pathogenesis, Diagnosis, and Therapeutic Implications of Intestinal Bacteria.Current issues in molecular biology · 2025Review
- New perspectives on microbiome-dependent gut-brain pathways for the treatment of depression with gastrointestinal symptoms: from bench to bedside.Journal of Zhejiang University. Science. B · 2025Review
- The role of gut microbiota in diarrhea and its alleviation through microbiota-targeted interventions.Frontiers in microbiology · 2025Review
- IBS May Have a Causal Effect on Increased Tryptophan Metabolites Levels: Insights from a Bidirectional Two-Sample Mendelian Randomization Study.International journal of tryptophan research : IJTR · 2025Article
- Exploring Gut Microbiota Imbalance in Irritable Bowel Syndrome: Potential Therapeutic Effects of Probiotics and Their Metabolites.Nutrients · 2024Review
- The Role of Gut Microbiome in Irritable Bowel Syndrome: Implications for Clinical Therapeutics.Biomolecules · 2024Review
- Review
- Chronically socially isolated mice exhibit depressive-like behavior regulated by the gut microbiota.Heliyon · 2024Article
- No Impact of Enteral Nutrition on Fecal Short-Chain Fatty Acids in Children with Cerebral Palsy.Biomedicines · 2024Article
- Effect of Tryptophan Restriction in the Therapy of Irritable Bowel Syndrome: a Systematic Review.International journal of general medicine · 2024Review
- Fecal short-chain fatty acids in non-constipated irritable bowel syndrome: a potential clinically relevant stratification factor based on catabotyping analysis.Gut microbes · 2023Article
- Colonic mucosal biopsy location can not affect the results of mucosal metabolomics and mucosal microbiota analysis in IBS.Frontiers in medicine · 2023Article
- Review of microbiota gut brain axis and innate immunity in inflammatory and infective diseases.Frontiers in cellular and infection microbiology · 2023Review
- Microbiota-gut-brain axis impairment in the pathogenesis of stroke: implication as a potent therapeutic target.Bioscience of microbiota, food and health · 2023Review
- Article
- Microbiome, Mycobiome and Related Metabolites Alterations in Patients with Metabolic Syndrome-A Pilot Study.Metabolites · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
Abstract
backgroundShort-chain fatty acids (SCFAs) and serotonin (5-hydroxytryptamine, 5-HT) may be associated with the pathogenesis of irritable bowel syndrome (IBS). There are some reports of alterations in SCFAs and 5-HT in IBS, but their results are inconsistent. We aimed to perform a meta-analysis to assess alterations in SCFAs and 5-HT in IBS patients and their potential role in the abnormal brain-gut-microbiota (BGM) axis.
methodsCase-control studies detecting SCFAs and 5-HT in IBS patients were identified from PubMed, Web of Science, Cochrane Library, and Scopus databases to identify relevant articles up to September 2018. The standardized mean differences (SMDs) with 95% confidence intervals (CIs) of SCFAs and 5-HT were calculated by REVIEW MANAGER 5.3 to evaluate the alterations of 5-HT and SCFAs in IBS.
resultsFive studies on SCFAs and 5 on 5-HT in IBS patients were included. As compared to healthy controls (HCs), the SMDs of 5-HT in IBS patients was 2.35 (95% CI 0.46-4.24) and the SMDs of total SCFAs, acetic acid, propionic acid, and butyric acid in IBS patients were - 0.01 (95% CI - 0.57-0.55), - 0.04 (95% CI - 0.55-0.47), 0.07 (95% CI - 0.45-0.60), and - 0.00 (95% CI - 0.49-0.49), respectively.
conclusionsThere was an increase in 5-HT in blood of IBS patients, indicating the increased 5-HT in blood may be involved in IBS pathogenesis. However, there were no significant differences in SCFAs in feces between IBS patients and HCs. But the study did not differentiate between subgroups of IBS. These findings might provide insight for future studies of the BGM axis in the pathogenesis of IBS. Mei Luo and Xiaojun Zhuang contributed equally to the writing of this article.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.